Dr Stock Pick HOT News & Alerts!
_______________________________________
FREE Daily Stock Alerts From DrStockPick.com
_______________________________________
Wednesday September 16, 2009
DrStockPick.com Stock Report!
PWRM, Power 3 Medical Products Inc, PWRM.OB
AMGN, Amgen Inc.
Power3 Medical Products, Inc. Headlines Session at International Molecular Diagnostic Meeting in China
- Power3 Medical Products, Inc. a Leader in Neurodegenerative Disease and Cancer Diagnostic Biomarkers Announces its Chief Scientific Officer is Chair and Keynote Speaker of Session at the BTI Life Sciences 2nd Annual Congress and Expo of Molecular Diagnostics in Beijing, China in November 2009 -
Power3 Medical Products, Inc. (OTC BB: PWRM), is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). Power3 expects to complete phase II clinical validation trials of its blood serum diagnostics for Alzheimer’s disease (NuroPro-AD), and Parkinson�s disease (NuroPro-PD) in 2009 and for breast cancer in 2010, followed by filings with the FDA. Power3 operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas. Power3 continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers it has discovered from a broad range of diseases as the basis of highly selective blood-based tests for ALS, Alzheimer’s, and Parkinson’s diseases, and breast cancer.
Power3 Medical Products announced today further international recognition of validity as the company�s President and CSO, Dr. Ira Goldknopf will deliver an invited Keynote address and chair a session on �Biomarkers and Diagnostics in Personalized Medicine (Track 6-4),� at the BIT Life Sciences 2nd International Congress and Expo of Molecular Diagnostics in Beijing, China, November 19-21, 2009. The Theme of the meeting is �New Leadership of Personalized Medicine.�
In his Keynote address, entitled �Principles of Omic Medicine Applied to Differential Diagnosis - Breast Cancer and Neurodegenerative Diseases,� Dr. Goldknopf will discuss the �necessary fundamental principles� that BC-SeraPro� and NuroPro� exemplify which enable the company�s biomarkers and tests to �more effectively address the unmet clinical needs that challenge us today.� He will describe the company�s unique position and ability to use biomarkers for testing in personalized medicine and the various facets that are required for discovery, validation and to commercialize a group of biomarkers.
�For physicians to order a test for a patient, they first need to believe in it. That takes major international scientific acceptance and publication in peer reviewed journals. This meeting is an excellent opportunity to showcase world-wide the strides we have made through refinements in our biomarkers and blood test for early stage detection of breast cancer (BC-SeraPro, GLOBE NEWSWIRE Aug. 20, 2009)� said Dr. Goldknopf. �Earlier presentations on Alzheimer�s and Parkinson�s disease biomarkers and tests were given at the annual meetings of the American Academy of Neurology in Seattle and the International Congress of Alzheimer�s Disease in Vienna (NuroPro, World Stock Wire July 14, 2009). We recently published the Parkinson�s disease biomarkers and test results in Biochemical and Biophysical Research Communications (Reuters Sept 2, 2009), and more publications are in the works.�
�We are extremely proud and excited about the recognition of Dr. Goldknopf and Power3 by the opportunity to chair this session and present at this international meeting.� said Ms Park, Power3�s CEO. �Dr. Goldknopf is the Keynote speaker and will feature new progress in clinical validation of the company�s biomarkers and blood test for early stage diagnosis of Breast cancer leading to commercialization.�
Amgen Inc. to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 - ESMO 34 Congress
- Key Denosumab and Vectibix(R) (Panitumumab) Data to be Presented -
Amgen Inc. (AMGN) discovers, develops, manufactures and delivers innovative human therapeutics. AMGN was one of the first companies to realize the new science’s promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient.
AMGN today announced it will present detailed data from four Phase 3 studies as well as other data at the ECCO 15 - ESMO 34 European Multidisciplinary Congress, September 20 - 24, 2009 in Berlin, Germany.
Researchers will present data from two Phase 3 head-to-head studies evaluating denosumab versus Zometa� (zoledronic acid) for the treatment of bone metastases in patients with advanced breast cancer (the ‘136′ study) and the treatment of bone metastases in advanced cancer patients with solid tumors (not including breast and prostate cancer) or multiple myeloma (the ‘244′ study).
Detailed data will also be presented from two Phase 3 studies evaluating Vectibix� (panitumumab) in combination with chemotherapy for the first-line and second-line treatment of metastatic colorectal cancer (the ‘203′ and ‘181′ trials, respectively).
“Amgen is very pleased to be presenting these important data from the denosumab and Vectibix development programs,” said Roger M. Perlmutter, M.D., Ph.D., executive vice president of Research and Development at Amgen. “The data from these trials demonstrate that both denosumab and Vectibix have the potential to improve outcomes in patients suffering from cancer.”
Keep a close eye on PWRM and AMGN today, do your homework, and like always BE READY for the ACTION!
No comments:
Post a Comment